

The microbiome and cancer for clinicians

Sarah L. Picardo^{a,*}, Bryan Coburn^b, Aaron R. Hansen^a

^a Division of Medical Oncology and Haematology, Princess Margaret Cancer Centre, 700 University Avenue, Toronto, Ontario, M5G 0A1, Canada

^b Division of Infectious Diseases, University Health Network, Toronto, Canada

ARTICLE INFO

Keywords:

Microbiome
Cancer therapeutics
Carcinogenesis

ABSTRACT

The human microbiome is an emerging target in cancer development and therapeutics. It may be directly oncogenic, through promotion of mucosal inflammation or systemic dysregulation, or may alter anti-cancer immunity/therapy. Microorganisms within, adjacent to and distant from tumors may affect cancer progression, and interactions and differences between these populations can influence the course of disease. Here we review the microbiome as it pertains to cancer for clinicians. The microbiota of cancers including colorectal, pancreas, breast and prostate are discussed. We examine “omics” technologies, microbiota associated with tumor tissue and tumor-site fluids such as feces and urine, as well as indirect effects of the gut microbiome. We describe roles of the microbiome in immunotherapy, and how it can be modulated to improve cancer therapeutics. While research is still at an early stage, there is potential to exploit the microbiome, as modulation may increase efficacy of treatments, reduce toxicities and prevent carcinogenesis.

1. The human microbiome

The microbiome of humans contains trillions of organisms distributed throughout the body, with the largest concentration in the genital tract and on other mucosal surfaces (McDonald et al., 2018). These organisms and their collective genomes - the human microbiome - develops from birth, with influence from both the maternal microbiota and the environment, and varies between individuals due to the cumulative effects of host factors and environmental exposures (Dominguez-Bello et al., 2010; Palmer et al., 2007). The composition and complexity of human-associated microbial communities has largely been defined using culture-independent sequencing of microbial ‘barcodes’ such as the 16S ribosomal RNA (rRNA) gene (for bacteria) (Human Microbiome Project, C., 2012a). However, the microbiome may be described as ‘the genes and genomes of the microbiota, as well as the products of the microbiota and the host environment’, which includes plasmid DNA and also viruses, archaea and fungi (although these are not generally detected at present) (Whiteside et al., 2015).

Dysbiosis or disruption of the normal human microbiota is associated with a wide range of diseases, including inflammatory bowel disease, multiple sclerosis, obesity, autism, depression, cardiovascular disease and allergy, as well as cancer (Forbes et al., 2016; Mowry and Glenn, 2018; Rodriguez et al., 2016; Sonnenburg and Backhed, 2016; Fung et al., 2017; Tang et al., 2013; Fujimura et al., 2016). The microbiome has been implicated in cancer in a variety of specific ways,

including being directly oncogenic, through promotion of oncogenic mucosal inflammation or systemic metabolic/immune dysregulation and through modulation of anti-cancer immunity or the efficacy of anti-cancer therapy (Kau et al., 2011; Dinan and Cryan, 2017; Mitsuhashi and Okuma, 2018; Floch et al., 2017; Uemura et al., 2001; Zhu et al., 2016; Di Domenico et al., 2017; Jackson et al., 2000; Zhan et al., 2011; Rogers, 2011; Rao et al., 2006; Xie et al., 2016; Bhatt et al., 2017; Boursi et al., 2015). Bacterial species are found in tumor tissue itself, normal tissue adjacent to tumor and at tumor sites such as the gut, genitourinary tract and airway, with overlap between these sites. Microorganisms within, adjacent to and distant from the tumor may play a role in cancer development and progression, and interactions and differences between these microbial populations, with their associated molecules and molecular pathways, have the potential to influence the course of disease (Fig. 1).

2. “Omics” analyses for the microbiome

Technologies for analysis of the human microbiome have developed within recent years, with numerous methods for quantification of the microbiome and its effects available, the most common of which are outlined in Table 1. The most frequently used methods are genomic sequencing of bacterial 16S ribosomal RNA (rRNA) and shotgun sequencing. Sequencing of the 16S rRNA gene provides relative quantitation of bacterial community composition, generally at the level of the

* Corresponding author.

E-mail addresses: sarah.picardo@uhn.ca (S.L. Picardo), bryan.coburn@utoronto.ca (B. Coburn), aaron.hansen@uhn.ca (A.R. Hansen).




Fig. 1. The relationship between various tumor types and the microbiome. Tumor tissue contains its own microbiome. Adjacent “normal” tissue also contains microbiota which may resemble the microbiome of the tumor, which suggests that alterations in bacterial species may play a causative role in tumor formation. Sites adjacent to the tumor such as feces and urine contain microbes, metabolites, inflammatory molecules and others which may influence tumorigenesis, tumor progression and response to treatment. Finally, bacteria in the gut as well as associated immune cells, cytokines, bacterial metabolites and other molecules may affect remote organs in terms of tumor formation and treatment response.

bacterial genus (Wang and Qian, 2009; Janda and Abbott, 2007; Pei et al., 2010), while shotgun sequencing analyses the entire genomic content of a sample and permits interpretation of the compositional and metagenomic abundance of microbial community members at high genomic resolution (Quince et al., 2017). The IS-pro technique is another method by which bacterial species can be characterized by amplifying 16S–23S rRNA gene interspace regions with lengths that are specific for each microbial species (Budding et al., 2016). Analysis of the metatranscriptome, or the mRNA of the microbial community, can reveal which organisms are active and which microbial genes are being expressed (Franzosa et al., 2014), but because of the short half-life of mRNA, represent a single time-point of gene expression that may not reflect longer-term adaptations between the host and microbiota (Bikel et al., 2015). Similarly, proteomics examines the protein content of samples such as feces, and again since protein expression is dynamic, this test gives an analysis of the expressed and functional proteins at a particular time point (Singhal et al., 2015; Jin et al., 2017). Finally, metabolomics is the study of the metabolites found in a sample, regardless of their organism of origin (host or microbial), and can include vitamins, short-chain fatty acids, bile acids, choline derivatives or polysaccharides, among many other compounds (Daliri et al., 2017). Collectively, these tools are used to characterize microbial taxonomic and metagenomic community composition and infer or measure microbial community and aggregate host/microbial metabolism to identify disease associations and novel targets for experimental, diagnostic or therapeutic studies.

3. The tumor-associated microbiome

The microbiome of tumor tissue itself has increasingly come under focus, with the realization that many tissues have their own bacterial, viral and fungal populations. While the microbiome of mucosal or exposed sites such as the gut, skin, mouth and vagina have been examined in more detail, the microbiome of non-mucosal tissues is less well characterized, in particular because controlling for contamination and validating results is challenging in these sample types. Microbial species have been identified in many tissue types with the advent of bacterial RNA sequencing, for example, in breast tissue and gastric tissue (Meng et al., 2018; Urbaniak et al., 2016; Ren et al., 2018). The tumor

microenvironment is a hypoxic one which is thought to facilitate the growth of anaerobic and facultative anaerobic bacteria such as *Clostridia* (Wei et al., 2007), while necrotic areas of the tumor can cause chemotactic compounds to be released, attracting bacterial invasion (Baban et al., 2010). The leaky vasculature of cancerous tissue also allows bacteria to enter, where the absence or low abundance of immune cells may permit growth (Syed Khaja et al., 2017). Indeed, intratumoral administration of non-pathogenic bacteria has been suggested as a mechanism of direct drug or therapeutic delivery (Cronin et al., 2010; Murphy et al., 2017).

Mucosal tumors are in direct contact with bacteria and therefore are susceptible to influence from the microbiome. The microbiome of colorectal cancer (CRC) has been extensively studied, as CRC is exposed to a vast array of bacterial species in the gut. Interestingly, the composition of fecal microbiota is not fully concordant with the composition of the tumor tissue microbiome (Flemer et al., 2017). Bacteria found in tumor tissue from CRC and other cancers are outlined in Table 2. *Fusobacteria* and *Firmicutes* are increased in tumor tissue compared to normal colonic tissue, while taxa including *Fusobacteria*, *Providencia* and *Actinobacter* are altered in abundance between cancerous and adjacent normal tissue (Gao et al., 2017a, 2015; Burns et al., 2015). *Fusobacterium nucleatum* in particular has been found in numerous studies to be enriched in colonic tumor tissue, although whether it is a causative agent or a bystander of some other process remains unclear, with animal models demonstrating conflicting results (Castellari et al., 2012; Kostic et al., 2012; Tomkovich et al., 2017; Yang et al., 2017; Yu et al., 2015a). The presence of these bacteria are also associated with histologic grade, CpG island methylation phenotype status, CD3 + T cell infiltration, resistance to chemotherapy and poorer overall survival (Koi et al., 2018; Lee et al., 2018; Mima et al., 2015, 2016; Flanagan et al., 2014; Ito et al., 2015; Yu et al., 2017; Tahara et al., 2014). Interestingly, *F. nucleatum* found in CRC may originate in the oral cavity, with identical strains of the bacteria found in matched tumor tissue and saliva (Komiya et al., 2018). The bacteria persists both in metastatic lesions and in tumor xenografts in mice; treatment of mice with these xenografts with metronidazole decreases tumor bacterial load and tumor growth, suggesting that the bacteria may have a role in tumor proliferation, although antibiotics may independently have anti-neoplastic effects (Bullman et al., 2017). A recent study suggested that

Table 1
“Omics” techniques for microbiome analysis.

Data type	Data collected	Analysis tools	Pros	Cons	Refs
16S ribosomal RNA sequencing	Sequencing of hypervariable 16S rRNA region allows classification of bacterial composition down to genus level	16S databases, OTU clustering, PICRUST	Easy to perform, provides information on bacterial composition, large number of databases for analysis	Unreliable for quantification of different bacteria, primer sequences and PCR conditions may differ between analyses	(Wang and Qian, 2009; Janda and Abbott, 2007; Pei et al., 2010)
Shotgun sequencing (metagenomics)	Sequencing of whole genomic content of sample obtained	Various assembly tools	Provides overall composition and abundance of bacteria, can be used for functional analysis	Large amount of data generated requiring analysis and storage, requires high sequencing depth, limited reference databases, expensive	(Quince et al., 2017)
IS-pro	Sequencing of 16S-23S interspace region	Automated software pipeline	Easy to perform, quick assay, identification to species level	Expensive, proprietary technology	(Budding et al., 2016)
Metatranscriptomics	Sequencing of transcribed bacterial RNA content of sample (RNAseq)		Gives snapshot of actual expression profile of bacterial community, may allow inference of functional pathways	Analysis not yet standardized, mRNA has short half-life, technical problems with host RNA contamination	(Franzosa et al., 2014; Bikel et al., 2015)
Metaproteomics	Global analysis of protein content of sample eg feces, tissue, usually by mass spectrometry	Search engines eg SEQUEST, analysis software eg MetaProteome Analyzer	Protein expression analysis may identify potential biomarkers and targets, gives functional data	Contamination and sample collection problems, protein expression is dynamic and changes over time, analysis not yet standardized	(Singhal et al., 2015; Jin et al., 2017)
Metabolomics	Identifies metabolites of microbial and host metabolism in samples eg feces, bodily fluids, usually by mass spectrometry or nuclear magnetic resonance spectrometry	No standardized analysis tools	Can be used dynamically to assess metabolites eg before and after treatment, data on host-microbiome interactions	Complex sample collection problems and analysis, only data on one time point, no data on whether host or microbiome has influenced metabolites	(Daliri et al., 2017)

colonization with *F. nucleatum* may differ between tumors with varying tumor microsatellite instability (MSI) status, and may exert immunosuppressive effects in MSI-high tumors but pro-inflammatory effects in MSI-normal tumors (Hamada et al., 2018; Hale et al., 2018; Kosumi et al., 2018). Infection in the form of bacteremia or endocarditis with *Streptococcus gallolyticus* has long been associated with colorectal cancer, and this species is also found in tumor tissue itself (Abdulmir et al., 2010).

Bacteria have been found in the tissues of upper gastrointestinal cancers such as biliary and esophageal cancers, and in cervical cancer, although their significance remains unclear (de Martel et al., 2009; Murata et al., 2004; Liu et al., 2018a; Lam et al., 2018). In lung cancer patients with a history of heavy smoking, tumor tissue was characterized by significantly lower abundance of *Acinetobacter* and *Acidovorax* and higher abundance of *Streptococcus* and *Prevotella* compared with tissue from patients with emphysema (Liu et al., 2018b), while the genera *Veillonella* and *Megasphaera* may act as biomarkers for lung cancer with good sensitivity and specificity (Lee et al., 2016a).

Non-mucosal tissues have also been shown to contain bacteria, although interpretation of these studies is limited by the potential for contamination and the lack of verification in other work. In pancreatic cancer, bacteria have been shown to migrate from the gut to the pancreas in both murine models, using fluorescent-labelled microbes and 16S sequencing, and in human tumors (Pushalkar et al., 2018). The microbiome can reprogram the immune microenvironment of the pancreas, with ablation of the microbiome allowing decreased myeloid suppressor cells and increased CD4+ and CD8+ T cells. Repopulation of the microbiome restores an immunosuppressive environment in the pancreatic tumor in mice, although this may not reproduce the normal gut microbiome as oral gavage may induce a higher bacterial load and translocation than in non-depleted mice. In a similar study, gut microbiome depletion decreased tumor burden in a pancreatic cancer murine model, an effect which was not seen in mice who lacked mature T and B cells (Sethi et al., 2018; Mitsuhashi et al., 2015). As previously mentioned, human breast cancer tissue has been found to contain its own specific microbiota, which differs from that of the overlying skin or from normal/control tissue (Meng et al., 2018; Hieken et al., 2016; Banerjee et al., 2015). Differences in microbial composition between breast cancer subtypes have been observed, with distinct patterns found in the triple negative and triple positive tumor types (Banerjee et al., 2018). Distinct microbiome profiles have been detected in the ovary, fallopian tubes and cervix, and may be associated with endometrial and ovarian cancers (Walther-Antonio et al., 2016; Brewster et al., 2016). Previous studies have shown bacterial DNA to be present in prostate cancer tissue (Keay et al., 1999; Krieger et al., 2000), identifying *Escherichia*, *Mycoplasma hominis* and *Cutibacterium* (formerly *Propionibacterium*) *acnes* among others (Sfanos et al., 2008; Barykova et al., 2011; Yow et al., 2017; Cohen et al., 2005; Cavarretta et al., 2017). When mice were inoculated via urethral catheterization with *C. acnes* and *E. coli* from prostatectomy specimens, severe inflammation was induced in prostate tissue, along with accelerated development of prostate adenocarcinoma (Shinohara et al., 2013; Simons et al., 2015). Inflammation in the prostate has been shown to merge with intraepithelial neoplasia (Putzi and De Marzo, 2000), while polymorphisms in the promoter regions of the genes of cytokines such as IL-8, IL-10 and VEGF are associated with risk for prostate cancer (McCarron et al., 2002), again suggesting links between inflammation and prostate cancer.

These findings indicate that tumor tissue may have a distinct microbiome – bacteria may enter the necrotic, tumor environment from adjacent body fluids, distant mucosal cavities or elsewhere, and may alter cell infiltrate thereby decreasing immune surveillance. Whether the presence of these bacteria is causative or simply a consequence of the dysfunctional environment of the tumor remains to be elucidated, and results need to be validated to ensure that bacterial species identified are not due to contamination. Some bacteria such as

Table 2
Tumor tissue-associated microbiome.

Tumor type	Bacteria	Associations	Ref
Colorectal	<i>Fusobacterium nucleatum</i>	Tumor grade, methylation status, immune cell infiltrate, chemotherapy response, poor prognosis	(Castellari et al., 2012; Kostic et al., 2012; Tomkovich et al., 2017; Yang et al., 2017; Yu et al., 2015a; Koi et al., 2018; Lee et al., 2018; Mima et al., 2015, 2016; Flanagan et al., 2014; Ito et al., 2015; Yu et al., 2017; Tahara et al., 2014)
	<i>Bifidobacterium</i>	Associated with signet ring cells	(Kosumi et al., 2018)
	<i>Streptococcus gallolyticus</i>	Associated with bacteremia/endocarditis, increased inflammatory markers eg IL-1, IL-8, COX-2	(Abdulmir et al., 2010)
Pancreas	Proteobacteria, Bacteroidetes, Firmicutes	Increased compared to normal tissue, may alter immune microenvironment	(Pushalkar et al., 2018)
Biliary tract cancers	<i>Fusobacterium</i>	Poor prognosis	(Mitsunashi et al., 2015)
	<i>Helicobacter bilis</i>	Found in tumor tissue	(de Martel et al., 2009)
Esophageal cancer	<i>Streptococcus</i> spp., <i>Prevotella</i> spp.	Poor prognosis, nodal status	(Liu et al., 2018a)
Breast cancer	Bacteroidaceae, <i>Agrococcus</i>	Tumor grade	(Meng et al., 2018)
	<i>Fusobacterium</i> , <i>Atopobium</i> , <i>Gluconacetobacter</i> , <i>Hydrogenophaga</i> , <i>Lactobacillus</i>	Malignancy	(Hieken et al., 2016)
	<i>Arcanobacterium</i> , <i>Bifidobacterium</i> , <i>Cardiobacterium</i> , <i>Citrobacter</i> , <i>Escherichia</i> , <i>Bordetella</i> , <i>Campylobacter</i> , <i>Chlamydia</i> , <i>Chlamydomydia</i> , <i>Legionella</i> , <i>Pasteurella</i> , <i>Streptococcus</i> , <i>Aerococcus</i> , <i>Arcobacter</i> , <i>Geobacillus</i> , <i>Orientia</i> , <i>Rothia</i>	Differentially abundant between breast cancer subtypes (hormone receptor positive, HER2 positive, triple positive, triple negative)	(Banerjee et al., 2018)
Cervical cancer	Bacillaceae, Halobacteriaceae, <i>Prevotella bivia</i>	Upregulate immune pathways	(Lam et al., 2018)
Prostate cancer	<i>Cutibacterium acnes</i>	Induces inflammation, increase in Ki-67 index, decrease in androgen receptor expression	(Cohen et al., 2005; Shinohara et al., 2013)
	<i>Escherichia coli</i>	Accelerated prostate adenocarcinoma development	(Simons et al., 2015)
	<i>Mycoplasma hominis</i> , Enterobacteriaceae, <i>Escherichia</i> , <i>Acinetobacter</i> , <i>Pseudomonas</i>	Increased compared to normal tissue	(Sfanos et al., 2008; Barykova et al., 2011; Yow et al., 2017)
Lung cancer	<i>Veillonella</i> , <i>Megasphaera</i>	Biomarker for cancer	(Lee et al., 2016a)
	<i>Acinetobacter</i> , <i>Acidovorax</i> , <i>Streptococcus</i> , <i>Prevotella</i>	Altered compared to emphysematous tissue	(Liu et al., 2018b)

Fusobacterium have been found in numerous studies and do appear to have pro-neoplastic capabilities, although its presence is not consistent, as discussed previously (Repas et al., 2016). As better models of tumorigenesis continue to be developed and with improved detection techniques for bacteria, their proteins and metabolites; the significance of these microbiota will become clearer.

4. The microbiome of tumor-adjacent “normal” tissue

While cancerous tissue itself appears to have an altered microbiome, it is known that many cancers appear to develop in previously inflamed tissues, raising the possibility that bacteria may have a “field effect” promoting the neoplastic process. Tissue adjacent to tumors are likely to be altered compared to true “normal” tissue, due to factors such as immune cell infiltrate, fibrosis and tumor-associated inflammation. Allali et al performed a study examining colorectal cancer and adjacent tissue from patients from the US and Spain (Allali et al., 2015). Tumor and adjacent tissues had very closely related microbiota, with lower diversity seen in tumor tissues, although significant differences were seen between the Spanish and US cohorts, suggesting a role for geographical and environmental factors. Nakatsu et al sampled colorectal tumor and adenomatous tissue and adjacent mucosa, and examined the 16S rRNA gene sequencing profiles of biopsies (Nakatsu et al., 2015). They divided the profiles into five “metacommunities” or clusters with the deepest taxonomic annotations, based on Dirichlet multinomial mixture models (Ding and Schloss, 2014), and found that meta-community E, containing *Fusobacterium* as well as other Firmicutes, and Proteobacteria were almost always found in both lesion-adjacent mucosa and in lesions themselves; Proteobacteria has also been found in adenoma-adjacent tissue (Lu et al., 2016).

In breast cancer, analysis of the TCGA database found bacteria present in both tumor and normal adjacent breast tissue, with

Proteobacteria, Actinobacteria and Firmicutes the main phyla noted in both tissue types (Thompson et al., 2017). Cancerous tissue of the breast contains lower numbers of bacteria compared with adjacent normal tissue, and this is associated with lower expression of anti-microbial response genes including Toll-like receptors and IL-12A; this suggests that alterations in the normal breast microbiome may cause changes in the inflammatory response during carcinogenesis (Xuan et al., 2014). In laryngeal cancer, tumor and adjacent normal tissue were found to have similar microbiota with an increase in the phylum *Fusobacterium* and a decrease in Firmicutes and Actinobacteria compared to the tissue of healthy controls (Gong et al., 2017). Interestingly, in a study of oral cancers, patients with higher T-stage disease had more similarities between tumor and adjacent non-tumor microbiomes than patients with lower T-stage disease; it may be that the bacteria in oral tissue predispose to a more proliferative tumor through a “field” dysbiosis (Mukherjee et al., 2017).

These findings suggest that tumor-adjacent “normal” tissue is in fact similar to tumor tissue, rather than truly normal tissue, in its microbial composition, and that these bacterial communities may form a micro-network within the tumor environment, causing altered inflammatory signaling. Supporting this hypothesis, transcription factors have been found to be dysregulated in colonic tumor-adjacent mucosa compared to healthy mucosa, suggesting a complex interaction between proteins and receptors on the tumor and the surrounding tissue (Sanz-Pamplona et al., 2014). Further studies incorporating numerous controls including normal tissue from non-cancerous patients are needed to validate these results.

5. The tumor-site microbiome

Many tumors are found at body cavities such as the gastrointestinal tract, airway and genitourinary tract, and these sites have their own

microbiomes, in particular the fecal microbiome. In the colon, *F. nucleatum* has been found in colorectal tumor tissue and is likely to have translocated from feces in the gut into colonic epithelium, inducing pro-inflammatory and oncogenic pathways (Flanagan et al., 2014; Rubinstein et al., 2013; Kostic et al., 2013; Zhou et al., 2018). It expresses a unique adhesion protein called FadA, which can bind to E-cadherin and allow the bacteria to invade CRC cells, causing β -catenin-regulated transcription of the oncogenes Myc and Cyclin D1, and increased cancer cell proliferation. Interestingly, in mouse models, fecal *F. nucleatum* does not appear to induce colitis or inflammation-associated colonic carcinogenesis, but recruits tumor-infiltrating immune cells and increases the number of colonic tumors (Kostic et al., 2013). In the same mouse model, *F. nucleatum* also induced colorectal tumors via the microRNA miR21, inhibitors of which prevented CRC cell line proliferation and invasion (Yang et al., 2017). MicroRNAs have been found to be differentially expressed in normal and tumor tissue in the colon, and to correlate with the microbiome profile of the colon, providing another method by which the gut epithelium can interact with bacteria (Yuan et al., 2018). *Campylobacter jejuni* causes mice to develop more and larger colorectal tumors compared with uninfected mice, an effect which is diminished by administration of the antibiotic rapamycin (He et al., 2018). Other species associated with CRC in the gut include *Escherichia coli* (Arthur et al., 2012), *Bacteroides fragilis* (Wang et al., 2012a), *Streptococcus bovis* (Krishnan and Eslick, 2014) and *Enterococcus faecalis* (Balamurugan et al., 2008). In particular, enterotoxigenic *Bacteroides fragilis* has been shown to induce colonic tumors in mice via IL-17 and possibly via Stat3-driven TH-17 T cell response (Wu et al., 2009; Housseau et al., 2016).

Metabolites produced by the host and by bacteria are increasingly being recognized as modulators of mucosal/epithelial health, cellular homeostasis, metabolism, inflammation and proliferation. Fermentation of fibre into short chain fatty acids (SCFA), and in particular butyrate, is essential for a healthy colonic mucosa (Roediger, 1982). Lower bacterial diversity along with lower SCFAs were associated with colonic tumors in mice, and restoration of the SCFA levels using sterols caused tumor apoptosis (Ma et al., 2018). Bacteria which produce butyrate have been found to be lower in abundance in stool of CRC patients compared with non-CRC patients (Wang et al., 2012a; Balamurugan et al., 2008); butyrate may decrease tumorigenesis and have anti-inflammatory and immunomodulatory effects (O'Keefe, 2016; Vipperla and O'Keefe, 2012). Interestingly, butyrate may also enhance the intestinal barrier function by upregulating the tight junction protein claudin-1 and by increasing mucin production; therefore decreases in butyrate due to dysbiotic changes in the gut bacteria may increase the leakiness of the intestinal epithelium and allow bacteria to enter tissue (Wang et al., 2012b; Willemsen et al., 2003). Deoxycholic acid (DCA) is a secondary bile acid which may be involved in intestinal tumorigenesis. When mice are treated with this bile acid, tumor formation is increased and the microbiota are altered (Cao et al., 2017). When feces from these mice were transplanted into non-treated mice, activation of the Wnt/ β -catenin pathway was observed, and inflammation and tumor number was increased.

As with all mucosal surfaces, the airway epithelium has a distinct microbiome which may be altered in many disease states including chronic obstructive pulmonary disease, cystic fibrosis, asthma and lung cancer (Mao et al., 2018). Airway brushings from lung cancer tissue have been shown to have decreased α -diversity (within-sample microbial diversity) and increased abundance of *Streptococcus* spp. compared with brushings from the contralateral non-cancerous lung (Liu et al., 2018c). Paired cancerous and non-cancerous brushings had lower diversity and altered compositions compared with healthy controls, suggesting an overall alteration in the airway microbiome in cancer patients. Enrichment of *Streptococcus* and *Veillonella* in lung cancer brushings was associated with upregulation of the PI3K and ERK pathways, which have been implicated in most lung cancers (Tsai et al., 2018), promoting proliferation, migration, invasion and resistance to

therapy (De Marco et al., 2017). *Haemophilus influenza* may promote tumor formation via IL-17C and neutrophil infiltration (Jungnickel et al., 2017), and can increase metastatic growth of lung cancers when inhaled by mice in combination with cigarette smoke (Jungnickel et al., 2015). The bacteria found in bronchial fluid from lung cancer patients may originate in the mouth and provide a link between the oral microbiome and the development of lung tumors (Hasegawa et al., 2014; Hosgood et al., 2014). We know that antibiotic use may reduce the efficacy of immune checkpoint inhibitor treatment in lung cancer, but it is as yet unknown whether this is due to modulation of the gut or the lung microbiome, or a direct anti-neoplastic effect (Derosa et al., 2018).

The urinary tract was long thought to be a completely sterile environment – to such a degree that in the Human Microbiome Project, commenced in 2008, urine was not one of the samples collected for analysis as the urinary tract was not thought to contribute to human microbiota (Human Microbiome Project, C., 2012b). In recent years, it has become apparent that the urinary tract has its own diverse microbiome. Historically, standard urinary culture methods did not detect slower-growing bacteria such as *Lactobacillus* and *Corynebacterium*, but these species can now be detected using sequencing of the hypervariable regions of the 16S rRNA gene (Human Microbiome Project, C., 2012a; Wolfe et al., 2012). The urothelium is continuously exposed to urine and its contents, and it is likely that, similar to the intestinal epithelium, there are reciprocal interactions between the microbes in urine and bladder tissue (Maynard et al., 2012). The link between infection with *Schistosoma haematobium*, a helminth endemic in the Middle East and Africa, and bladder cancer has long been recognized (Humans, I.W.G.o.t.E.o.C.R.t. and C., 2012). It is thought that the helminths release carcinogenic estrogen-like metabolites, nitrosamines and cyclooxygenase-2 which lead to tumorigenesis (Gouveia et al., 2015; Yongvanit et al., 2012), while they can also alter the abundance of *Fusobacterium* and other bacteria found in the urine (Adebayo et al., 2017). Popovic et al have examined the urinary microbiome in bladder cancer (Bucevic Popovic et al., 2018), finding high inter-individual variability but enrichment of *Fusobacterium*, *Campylobacter* and *Ruminococcaceae* in the cancer group. When *F. nucleatum* was further investigated, 16S rRNA was found in 11 of 42 (26%) bladder tumor tissue samples. Other changes in the urinary microbiome in bladder and prostate cancer patients are shown in Table 3. Interestingly, seminal fluid in mice has also been shown to have its own microbiome, influenced by the presence of a functional *ESR1* gene, which has been implicated in prostate cancer risk (Javurek et al., 2016; Liu et al., 2018d; Hao et al., 2016).

The microbiome of the oral cavity has been studied in the Oral Microbiome Project, which includes 770 microbial species found in the human mouth. The oral microbiome may be influenced by many factors such as oral hygiene, smoking, diet and alcohol consumption (Fan et al., 2018a; Hsiao et al., 2018). In oral cancers, disruption of the normal microbiota has been found, with dynamic changes across the stages of oral squamous cell carcinoma (Yost et al., 2018; Yang et al., 2018a) (Table 3). A biomarker panel of seven genera of bacteria can distinguish oral cavity and oropharyngeal cancers from healthy controls, although whether these bacteria have any prognostic significance is unclear (Lim et al., 2018). The vaginal microbiome has been examined in the context of gynecological cancers; associations have been found between bacteria, the rate of clearance of the oncogenic virus HPV and cervical intraepithelial neoplasia (Brotman et al., 2014; Oh et al., 2015; Seo et al., 2016; Audirac-Chalifour et al., 2016; Champer et al., 2018).

Overall, it appears that the tumor site microbiome differs significantly from that of non-tumor sites within the gut, lung, genitourinary tract and oral cavities, among others. It is possible that either dysbiotic bacteria themselves, or their products such as butyrate and other short-chain fatty acids, cause alterations in the adjacent mucosal surfaces, including direct bacterial invasion, increases in neutrophil and other immune cell infiltrates, expression of cytokines such as IL-17 and upregulation in oncogenic pathways involving genes such as ERK, PI3K,

Table 3
The microbiome of tumor sites in various cancer types.

Sample type	Tumor type	Bacteria	Effect	Ref
Feces	CRC	<i>Fusobacterium nucleatum</i>	Induces tumorigenesis via miR21, increases tumor multiplicity, recruits immune cells, induces oncogene expression via E-cadherin binding and B-catenin signaling	(Yang et al., 2017; Rubinstein et al., 2013)
		<i>Campylobacter jejuni</i>	Produces cytolethal distending toxin causing dsDNA breaks, increases tumor growth and multiplicity	(He et al., 2018)
		<i>Escherichia coli</i> <i>Bacteroides fragilis</i>	Inflammation and increased tumor formation Induces colonic tumors via IL-17, induces Stat3-driven TH-17 T cell response	(Arthur et al., 2012) (Wang et al., 2012a; Wu et al., 2009; Housseau et al., 2016)
Airway		Butyrate-producing bacteria eg <i>Roseburia</i> , <i>E. rectale</i> and <i>F. prausnitzii</i>	Decreased in CRC patient feces, associated with decreased butyrate which may cause increased tumorigenesis	(Wang et al., 2012a; Balamurugan et al., 2008)
	Lung	<i>Haemophilus influenza</i>	Promote tumor formation via IL-17C and neutrophil infiltration, increase metastatic growth	(Jungnickel et al., 2017)
Urine	Bladder	<i>Streptococcus</i> , <i>Veillonella</i> <i>Fusobacterium</i> , <i>Campylobacter</i> and <i>Ruminococcaceae</i>	Increased in cancer compared with controls	(Tsay et al., 2018)
	Prostate	<i>Acinetobacter</i> , <i>Anaerococcus</i> and <i>Sphingobacterium</i> <i>Veillonella</i> , <i>Streptococcus</i> , <i>Bacteroides</i> , <i>E. coli</i> , <i>Anerococcus</i> spp., <i>Propionibacterium</i>	Increased in cancer compared with controls Increased in cancer compared with controls	(Bucevic Popovic et al., 2018) (Wu et al., 2018b)
Oral	Head and neck cancers	<i>Fusobacterium periodonticum</i> , <i>Parvimonas micra</i> , <i>Streptococcus constellatus</i> , <i>Haemophilus influenza</i> , and <i>Filifactor alocis</i> <i>Lactobacillus gasseri</i> and <i>Lactobacillus iners</i>	Increased with increasing stage of cancer	(Yu et al., 2015b) (Cavarretta et al., 2017; Shrestha et al., 2018; Alaneer et al., 2019) (Lim et al., 2018)
Vaginal	Cervical cancer	<i>Atopobium vaginae</i> , <i>G. vaginalis</i> and <i>Fusobacterium</i>	Altered clearance of HPV Associated with cervical intraepithelial neoplasia	(Brotman et al., 2014; Oh et al., 2015), (Seo et al., 2016; Audirac-Chalifour et al., 2016; Champer et al., 2018)

Wnt/B-catenin and STAT3. The alterations in the immune micro-environment may explain why microbiome composition affects the efficacy of immune checkpoint inhibitors (discussed below), and why antibiotic treatment may also influence these therapies.

The “common ground” hypothesis, postulated by Lynch et al in 2016, proposed that changes in the microbiota, instigated by an environmental factor such as diet or chronic infection, lead to polygenic changes which cause disease, such as cancer, in a host with genetic susceptibility (Lynch and Pedersen, 2016). While this remains a theoretical explanation, many of the studies examined here support this hypothesis. It appears that lower diversity of the microbiota is associated with the presence of tumor – this decrease in diversity may be present in tumor-adjacent normal tissue, suggesting that this change may be a precursor to the development of cancer and may even be a causative factor. The considerable variation in both the microbiota of various body sites and in the genetic susceptibility of hosts leads to the heterogeneity of studies attempting to establish causation by specific bacteria in human diseases. Further studies with adequate controls are needed to validate many of the findings described here.

6. Indirect effects of the gut microbiome in cancer

The microbiome of the gut can vary in patients with non-gastro-intestinal tumors such as pancreatic cancer and hepatocellular cancer (HCC) (Table 4) (Grat et al., 2016). In pancreatic cancer, the bacteria found in the tumor microenvironment are similar to those found in the gut. As previously described, bacteria can translocate from the gut to the pancreas (Pushalkar et al., 2018; Geller et al., 2017), while in murine models, ablation of the fecal microbiome protected against development of cancer and altered the immune cell infiltrate, with transfer of feces from cancer-bearing mice reversing this effect (Pushalkar et al., 2018; Sethi et al., 2018). Obese mice demonstrate alterations in their gut microbiota which leads to increased DCA production and induction of a secretory phenotype in hepatic stellate cells which promotes carcinogenesis in the liver, while blocking DCA or reversing the bacterial changes can prevent HCC development (Yoshimoto et al., 2013).

Post-menopausal patients with breast cancer have been shown to have lower gut flora diversity, an oestrogen-independent effect, and altered IgA-associated microbes, compared with post-menopausal controls (Goedert et al., 2015; Zhu et al., 2018), while the composition of the fecal microbiome differs with varying stages of breast cancer (Luu et al., 2017). The feces of lung cancer patients also varies in bacterial composition (Table 4) [30416659], a dysbiosis which was suggested may lead to a low concentration of butyrate and thereby contribute to cancer proliferation. As described in a later section, it has been shown that alterations in the gut microbiome can affect response to immunotherapy in renal cell carcinoma, melanoma and lung cancers. Differences in the gut bacterial composition have been noted between patients with and without prostate cancer, with increased α -diversity and altered composition (Liss et al., 2018; Sfanos et al., 2018; Golombos et al., 2018), while patients on oral anti-androgen therapy for prostate cancer also have alterations in their gut microbiome, although again the significance of these changes are unclear (Sfanos et al., 2018).

Interestingly, in mice in whom the gut microbiome was altered by disinfection by-products in water, metabolomic analysis of the urine revealed significant changes in metabolites in urine, including the polyamine spermine, which has previously been linked to many cancers including prostate, RCC and others (Gao et al., 2017b; Rioux-Leclercq et al., 2004; Sandsmark et al., 2017; Murray-Stewart et al., 2016), suggesting that the microbiota of the gut alters metabolites in remote sites by some mechanism. The composition of the oral microbiome may be associated with non-oral cancers, such as gastric cancer (Wu et al., 2018a), pancreatic cancer (Olson et al., 2017; Maisonneuve et al., 2017; Fan et al., 2018b; Bracci, 2017) and colon cancer (Table 4), with numerous bacterial species found in the mouth involved in biofilm

Table 4
Indirect effects of gut microbiome in various cancer types.

Sample type	Tumor type	Bacteria	Effect	Ref
Feces	Pancreas	Bifidobacterium pseudolongum	Translocates to pancreas, accelerates oncogenesis in murine model	(Pushalkar et al., 2018)
	Hepatocellular cancer	<i>Proteobacteria</i> , <i>Synergistetes</i> , and <i>Euryarchaeota</i> <i>Escherichia coli</i>	Increased in feces of PDAC patients compared to controls Increased in feces of HCC patients compared to cirrhotic controls	(Pushalkar et al., 2018) (Grat et al., 2016)
	Breast cancer	<i>Clostridium coccoides</i> , <i>Faecalibacterium prausnitzii</i> , <i>Blautia</i>	Lower diversity, variation in fecal microbiota with stage of cancer	(Goedert et al., 2015; Zhu et al., 2018; Luu et al., 2017)
	Lung cancer	Bacteroides, Veillonella, and Fusobacterium	Increased in feces of lung cancer patients compared with controls	(Zhang et al., 2018)
Oral microbiome		Escherichia, Shigella, Kluyvera, Fecalibacterium, Enterobacter, and Dialister	Decreased in feces of lung cancer patients compared with controls	(Zhang et al., 2018)
	Prostate cancer	Bacteroides and Streptococcus	Increased compared with controls	(Liss et al., 2018; Sianos et al., 2018)
	Gastric cancer	<i>Akkermansia muciniphila</i> and Ruminococcaceae spp	Increased in patients on oral anti-androgen therapy	(Sianos et al., 2018)
	Pancreatic cancer	Increase in Firmicutes and a decrease in Bacteroidetes <i>Porphyromonas gingivalis</i> and <i>Aggregatibacter actinomycetemcomitans</i>	Altered compared with controls Associated with periodontal disease and pancreatic cancer development	(Wu et al., 2018a) (Olson et al., 2017; Maisonneuve et al., 2017; Fan et al., 2018b; Bracci, 2017)
	Colon cancer	<i>Treponema denticola</i> , <i>Prevotella</i> spp., <i>Streptococcus</i>	Increased compared with controls, biofilm formation	(Klimesova et al., 2018; Yang et al., 2018b; Flemer et al., 2018)

formation, pro-inflammatory stimulation and colorectal carcinogenesis (Klimesova et al., 2018; Yang et al., 2018b; Flemer et al., 2018).

The effects of alterations of the microbiome in the gut, and potentially in other sites, may cause long-distance effects in organs such as the liver, breast, lung and prostate. The method by which this modulation occurs remains unexplained – it may be that bacterial metabolites such as bile acids, fatty acids and polyamines induce carcinogenesis in remote organs. Stimulation of the rich immune system of the gut could lead to alterations in immune cell populations and small molecule expression which in turn provoke tumor formation. It may be that oncogenic bacteria translocate directly from one body site to another, as may occur in the pancreas. Once the mechanisms by which this effect occurs are revealed, the microbiome may be exploited to influence the processes of carcinogenesis and tumor progression.

7. Immunotherapy and the microbiome

There is growing evidence that the human microbiome can affect the efficacy of immunotherapy. The advent of checkpoint inhibitors and the widespread use of this type of immunotherapy has uncovered a new interaction between cancer treatment and the microbiome. In patients with metastatic melanoma treated with the anti-CTLA-4 antibody ipilimumab, gut microbiota enriched with *Fecalibacterium* and other Firmacutes was found to be associated with longer progression-free survival (PFS) and overall survival (OS) than microbiota driven by Bacteroides (Chaput et al., 2017). Interestingly, colitis as an adverse effect of the treatment was also associated with the beneficial microbiota profile, suggesting that this may be a marker of response to treatment. More recently, the gut microbiome profile in melanoma patients was associated with response to treatment with anti-programmed cell death protein-1 (anti-PD-1) antibodies, with abundance of the Ruminococcaceae family in responders (Gopalakrishnan et al., 2018). Transplantation of the feces of responders into germ-free mice enhanced systemic and anti-tumor immunity. In a similar study in metastatic melanoma, patients who responded to immunotherapy had fecal profiles enriched with *Bifidobacterium longum*, *Collinsella aerofaciens*, and *Enterococcus fecium* (Matson et al., 2018). Mouse models of melanoma have also identified *Bifidobacterium* as being associated with antitumor immunity; oral administration of *Bifidobacterium* had similar tumor control rates to administration of anti-PD-1 ligand (anti-PD-L1) therapy, and co-administration of both almost completely abolished tumor growth, suggesting this bacteria as a promising adjunctive therapy to checkpoint inhibitors (Sivan et al., 2015).

In patients with advanced cancers treated with immunotherapy, resistance was associated with an abnormal gut microbiome and with antibiotic therapy (Routy et al., 2018). In this study, abundance of *Akkermansia muciniphila* was associated with response to treatment. When germ-free mice were inoculated with feces from non-responders, their response was restored by oral supplementation with *A. muciniphila*. This bacterial species is enriched in patients with prostate cancer who have been treated with anti-androgen therapy; and may enhance response to subsequent or concurrent immunotherapy in these patients. Antibiotic treatment in patients with advanced RCC and non-small cell lung cancer (NSCLC) decreased the effectiveness of anti-PD-L1 monoclonal antibody treatment. Patients who had recent antibiotic treatment had a higher risk of primary progressive disease, shorter PFS and shorter OS in RCC and NSCLC (Derosa et al., 2018). Prior exposure to antibiotics such as penicillins, cephalosporins and macrolides increased the risk of cancers including lung, gastric, prostate and breast cancers even after adjusting for smoking status and number of infections, suggesting that alterations in the microbiome may predispose to cancer development [26338196].

8. Modulation of the microbiome and its role in cancer therapeutics

Given the significant role that the microbiome appears to play in cancer, modulation of the microbiota may allow alteration of the course of disease. There are many ways in which the microbiome can be modified. Prebiotics are defined as substrates that are selectively used by host micro-organisms conferring a health benefit, with the most studied being oligosaccharides which promote Bifidobacteria and appear to improve conditions such as type 2 diabetes mellitus, metabolic syndrome and allergies among many (Anon., 2019; Roberfroid et al., 2010). Probiotics are live micro-organisms that, when administered in adequate amounts, confer a health benefit, and again have been shown to have wide-ranging effects on various health-related conditions including supporting a healthy digestive tract (Hill et al., 2014; Ritchie and Romanuk, 2012). Synbiotic treatment involves a combination of pre- and pro-biotics in an attempt to synergize the effects of both bacteria and substrates, and has been used in treatment of many conditions such as pancreatitis, non-alcoholic steatohepatitis and childhood eczema (Markowiak and Slizewska, 2017; Zhang et al., 2010; Eslamparast et al., 2014; Dang et al., 2013). Apart from oral “biotic” supplementation, fecal microbiota transplantation (FMT) is the most widely recognized technique used to modify the microbiome. FMT has a demonstrated benefit in recurrent or refractory *Clostridium difficile* infection (van Nood et al., 2013; Cammarota et al., 2015; Lee et al., 2016b), and has also been used in treatment of ulcerative colitis and metabolic syndrome (Vrieze et al., 2012; Moayyedi et al., 2015).

Modulation of the microbiome can be exploited in cancer therapeutics. Firstly, since the microbiome appears to be involved in the process of carcinogenesis, manipulation of microbiota may help in cancer prevention. Recent work in a mouse model of colonic carcinogenesis showed that oral intake of a probiotic supplement containing *Lactobacillus helveticus* could decrease IL-17-producing T cells and suppress hyperplasia and tumor formation, possibly by altering the gut microbiome (Rong et al., 2018). Synbiotic administration can also alter fecal microbiota, reduce colonic proliferation and increase epithelial barrier function in patients with resected colonic polyps or tumours (Rafter et al., 2007). There is also potential to genetically modify microbes, as well as to use antibiotics, drugs targeting bacterial-induced inflammation or genotoxins, to prevent carcinogenesis (Khazaie et al., 2012; Schwabe and Jobin, 2013). An interesting study from the National Institute of Health examined the 21 common laboratory mouse strains and compared their microbiota to that of a closely related wild relative (Rosshart et al., 2017). When laboratory mice were reconstituted with natural “wild-type” microbiota, they had increased resistance to mutagen and inflammation-induced colorectal tumorigenesis. Modulating the microbiome in the pre-cancerous phase of disease may provide a mechanism to prevent cancer development.

Altering the microbiota can affect cancer growth and prevent cancer recurrence. In a mouse model of inflammation-induced colonic tumors, probiotic supplementation decreased tumor cell proliferation and tumor number, downregulated NF- κ B activation and promoted beneficial commensal bacteria in the gut (Rong et al., 2018). Another interesting study in a murine melanoma model demonstrated that aerosolized probiotic treatment could promote immunity against lung metastases, representing another delivery method for microbiome modulation (Le Noci et al., 2018). Administration of *Lactobacillus acidophilus* to mice with breast tumors altered cytokine production and reduced tumor growth, possibly altering the microbiome in the gut, tumor or other location (Maroof et al., 2012). A number of trials have shown effectiveness of probiotic supplements in patients with bladder cancer. A double-blind randomized trial in 138 patients with primary bladder cancer reported that daily oral administration of an oral *Lactobacillus casei* preparation prevented recurrence after transurethral resection of tumors compared with placebo (Aso et al., 1995). Another retrospective study demonstrated some possible effect of previous

intake of fermented milk products on decreasing risk of bladder cancer [12053032]. A more recent prospective randomized controlled trial in 207 patients demonstrated that 3-year recurrence free survival after transurethral bladder tumor resection was improved with intravesical epirubicin and 1 year of *Lactobacillus casei* compared with intravesical epirubicin alone (Naito et al., 2008). These intriguing results suggest that oral supplementation with bacteria may alter the fecal and/or urinary microbiome and thereby influence neoplastic disease in the bladder.

Microbiome modulation can also be used as an adjunct to standard cancer treatment. In 2013, it was shown in murine models that germ-free or antibiotic-treated animals did not respond to platinum-based chemotherapy, indicating that an intact microbiome was required for modulating the myeloid-derived immune cell responses in the tumor microenvironment (Iida et al., 2013). In the same year, Viaud et al. showed that germ-free or antibiotic-treated mice demonstrated decreased translocation of Gram-positive bacteria into lymphoid organs, a reduction in T helper-17 cells and diminished response to cyclophosphamide, while transfer of T helper-17 cells restored the efficacy of cyclophosphamide (Viaud et al., 2013). Oral gavage with *Enterococcus hirae* also restored tumor responsiveness to cyclophosphamide (Daillere et al., 2016). Cisplatin is a platinum-based chemotherapeutic agent that can cause breaching of the intestinal epithelial barrier and translocation of gut bacteria to the bloodstream. In mice with ovarian tumors, cisplatin damaged the intestinal epithelium and altered the gut commensal flora, an effect which was abrogated by administration of *Ruminococcus gnavus* and fecal pellet gavage (Perales-Puchalt et al., 2018). In a mouse lung cancer model, concurrent antibiotics decreased the effectiveness of cisplatin, while supplementation with *Lactobacillus* decreased tumor size and improved survival, suggesting that in fact cisplatin-induced intestinal damage and alteration of the microbiome may be a part of its anti-tumoral activity (Gui et al., 2015). In a mouse model of colon cancer, intratumoral Gammaproteobacteria could metabolize gemcitabine into its inactive form, an effect which was abrogated by treatment with the antibiotic ciprofloxacin (Geller et al., 2017); interestingly, this bacteria was found in 76% of human pancreatic cancer tissue samples, suggesting that this may be a mechanism by which these tumors become resistant to treatment with gemcitabine.

There are suggestions from animal models that alterations in the microbiome may affect the response to newer therapies such as adoptive T cell transfer. In mice treated with adoptive T cell therapy, changes were observed in the gut microbiome; when the mice were treated with oral vancomycin (which does not cross the intestinal barrier), changes in abundance of Bacteroidetes and Firmicutes were seen, and tumor progression was reduced, providing evidence that the gut microbiota can influence the efficacy of adoptive T cell therapy (Uribe-Herranz et al., 2018).

Finally, modulation of the microbiome may be useful in treatment of cancer-related and therapy-related effects. Chemotherapy can cause severe imbalances in the gut microbiome which alter metabolic pathways – this has the potential to be modified (Montassier et al., 2015). Treatment with synbiotics containing *Bifidobacterium breve* and *Lactobacillus casei* along with galacto-oligosaccharides decreased complications such as diarrhea, neutropenia and lymphopenia in patients receiving neoadjuvant chemotherapy for esophageal cancer (Motoori et al., 2017). Probiotics have also been used to improve diarrhea associated with 5-fluorouracil chemotherapy and radiation in numerous gynecological and gastrointestinal tumour types (Osterlund et al., 2007; Lalla et al., 2014; Ferreira et al., 2014). Fecal transplantation can be used in treatment of immunotherapy-related colitis (Wang et al., 2018).

The numerous studies described here suggest that pre-/pro-/synbiotic supplementation and fecal transplantation may have cancer preventative effects, and may also be used as adjunct treatments in many cancer types. Used alone or combined with standard chemotherapy or immunotherapy, microbiome modulation may enhance the efficacy and decrease side effects of these treatments, prevent

disease recurrence and decrease metastases.

9. Confounding factors and limitations in microbiome research

Much of the research described here involves small studies with limited data on clinical factors and controls. There are many confounding factors that may influence the microbiome which larger-scale studies need to address in their design. There are differences in microbial composition between males and females, which may be affected by factors such as sex hormones, body size and even mood (Pala et al., 2019; Raju et al., 2019; Taylor et al., 2019). Smoking can influence the lung microbiome (Greathouse et al., 2018; Yu et al., 2016) in addition to the gut microbiome (Vogtmann et al., 2015; Benjamin et al., 2012), while smoking cessation can also induce changes in the intestinal microbiota (Biedermann et al., 2013). The gut microbiome of populations who consume different diets varies dramatically, with large differences in both microbes and metabolites seen between rural Africans and African-Americans, groups who have low and high risk of colon cancer development respectively (Ou et al., 2013); when their diets were reversed, rural Africans who were fed high-fat, low-fibre diets developed increased stool *F. nucleatum* levels, suggesting this as a mechanism for the carcinogenic risk (O'Keefe et al., 2015). Other factors including stent insertion or other instrumentation, bowel preparation and medications such as proton pump inhibitors (PPIs) and metformin can also influence the microbiome (Buhmann et al., 2019; Vaishnavi et al., 2018; Scheufele et al., 2017; Mishiro et al., 2018; Jalanka et al., 2015; Hojo et al., 2018; Wu et al., 2017). Therefore, future investigation into the role of the microbiome in cancer needs to account for all of these potential confounders. Many of the studies described in this review are limited by lack of or inadequate control samples and lack of validation in independent cohorts or further research. This limits our ability to draw conclusions or critically analyze much of the available data on the human microbiome and cancer.

10. Conclusions

From the evidence reviewed here, it is clear that the microbiome plays a complex role in human cancers. We know that the microbiome is influenced by many factors including environmental, dietary and genetic variations. The human microbiome is an emerging target in the field of cancer development and therapeutics. While much of this research is still at an early stage and the technologies used for analysis continue to evolve, there is obvious potential to utilize the microbiota of various sites in the body to predict cancer development and to act as a prognostic biomarker in cancers. A growing body of evidence suggests that the microbiome can influence response to immunotherapy, chemotherapy and newer cell transfer therapies. Modulation of the microbiome may provide methods to increase efficacy of treatments, reduce treatment toxicities and even to prevent carcinogenesis. While work has been done on the fecal microbiome, little research exists examining the role of the microbiota of tissue and of tumor-site fluids such as urine and mucus in tumorigenesis and treatment response, and further work is needed to delineate the influence of confounding factors on bacterial composition. Well-designed, controlled, structured, observational and interventional studies of the microbiome in cancer development and treatment are needed to assess disease associations and the diagnostic and therapeutic potential of the microbiome in human cancers across organ sites.

Funding sources

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Acknowledgements

There are no additional acknowledgements. All named authors contributed significantly to this manuscript.

References

- Abdulamir, A.S., Hafidh, R.R., Bakar, F.A., 2010. Molecular detection, quantification, and isolation of *Streptococcus gallolyticus* bacteria colonizing colorectal tumors: inflammation-driven potential of carcinogenesis via IL-1, COX-2, and IL-8. *Mol. Cancer* 9, 249.
- Adebayo, A.S., et al., 2017. The microbiome in urogenital schistosomiasis and induced bladder pathologies. *PLoS Negl. Trop. Dis.* 11 (8) p. e0005826.
- Alane, S., et al., 2019. A prospective study to examine the association of the urinary and fecal microbiota with prostate cancer diagnosis after transrectal biopsy of the prostate using 16S rRNA gene analysis. *Prostate* 79 (1), 81–87.
- Allali, I., et al., 2015. Gut microbiome compositional and functional differences between tumor and non-tumor adjacent tissues from cohorts from the US and Spain. *Gut Microbes* 6 (3), 161–172.
- Anon. !!! INVALID CITATION !!! { }.
- Arthur, J.C., et al., 2012. Intestinal inflammation targets cancer-inducing activity of the microbiota. *Science* 338 (6103), 120–123.
- Aso, Y., et al., 1995. Preventive effect of a *Lactobacillus casei* preparation on the recurrence of superficial bladder cancer in a double-blind trial. The BLP Study Group. *Eur. Urol.* 27 (2), 104–109.
- Audirac-Chalifour, A., et al., 2016. Cervical microbiome and cytokine profile at various stages of cervical cancer: a pilot study. *PLoS One* 11 (4) p. e0153274.
- Baban, C.K., et al., 2010. Bacteria as vectors for gene therapy of cancer. *Bioeng. Bugs* 1 (6), 385–394.
- Balamurugan, R., et al., 2008. Real-time polymerase chain reaction quantification of specific butyrate-producing bacteria, *Desulfovibrio* and *Enterococcus faecalis* in the feces of patients with colorectal cancer. *J. Gastroenterol. Hepatol.* 23 (8 Pt 1), 1298–1303.
- Banerjee, S., et al., 2015. Distinct microbiological signatures associated with triple negative breast cancer. *Sci. Rep.* 5, 15162.
- Banerjee, S., et al., 2018. Distinct microbial signatures associated with different breast cancer types. *Front. Microbiol.* 9, 951.
- Barykova, Y.A., et al., 2011. Association of *Mycoplasma hominis* infection with prostate cancer. *Oncotarget* 2 (4), 289–297.
- Benjamin, J.L., et al., 2012. Smokers with active Crohn's disease have a clinically relevant dysbiosis of the gastrointestinal microbiota. *Inflamm. Bowel Dis.* 18 (6), 1092–1100.
- Bhatt, A.P., Redinbo, M.R., Bultman, S.J., 2017. The role of the microbiome in cancer development and therapy. *CA Cancer J. Clin.* 67 (4), 326–344.
- Biedermann, L., et al., 2013. Smoking cessation induces profound changes in the composition of the intestinal microbiota in humans. *PLoS One* 8 (3), e59260.
- Bikel, S., et al., 2015. Combining metagenomics, metatranscriptomics and viromics to explore novel microbial interactions: towards a systems-level understanding of human microbiome. *Comput. Struct. Biotechnol. J.* 13, 390–401.
- Boursi, B., et al., 2015. Recurrent antibiotic exposure may promote cancer formation—Another step in understanding the role of the human microbiota? *Eur. J. Cancer* 51 (17), 2655–2664.
- Bracci, P.M., 2017. Oral health and the oral microbiome in pancreatic cancer: an overview of epidemiological studies. *Cancer J.* 23 (6), 310–314.
- Brewster, W.R., Ko, E.M., Keku, T.O., 2016. An evaluation of the microbiota of the upper genital tract of women with benign changes and epithelial ovarian. *Cancer* 34 (15 suppl), 5568.
- Brotman, R.M., et al., 2014. Interplay between the temporal dynamics of the vaginal microbiota and human papillomavirus detection. *J. Infect. Dis.* 210 (11), 1723–1733.
- Bucevic Popovic, V., et al., 2018. The urinary microbiome associated with bladder cancer. *Sci. Rep.* 8 (1), 12157.
- Budding, A.E., et al., 2016. Automated broad-range molecular detection of Bacteria in clinical samples. *J. Clin. Microbiol.* 54 (4), 934–943.
- Buhmann, M.T., et al., 2019. Encrustations on ureteral stents from patients without urinary tract infection reveal distinct urotypes and a low bacterial load. *Microbiome* 7 (1), 60.
- Bullman, S., et al., 2017. Analysis of *Fusobacterium* persistence and antibiotic response in colorectal cancer. *Science* 358 (6369), 1443–1448.
- Burns, M.B., et al., 2015. Virulence genes are a signature of the microbiome in the colorectal tumor microenvironment. *Genome Med.* 7 (1), 55.
- Camarota, G., et al., 2015. Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent *Clostridium difficile* infection. *Aliment. Pharmacol. Ther.* 41 (9), 835–843.
- Cao, H., et al., 2017. Secondary bile acid-induced dysbiosis promotes intestinal carcinogenesis. *Int. J. Cancer* 140 (11), 2545–2556.
- Castellari, M., et al., 2012. *Fusobacterium nucleatum* infection is prevalent in human colorectal carcinoma. *Genome Res.* 22 (2), 299–306.
- Cavarretta, I., et al., 2017. The microbiome of the prostate tumor microenvironment. *Eur. Urol.* 72 (4), 625–631.
- Champer, M., et al., 2018. The role of the vaginal microbiome in gynaecological cancer. *BJOG* 125 (3), 309–315.
- Chaput, N., et al., 2017. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. *Ann. Oncol.* 28 (6), 1368–1379.
- Cohen, R.J., et al., 2005. *Propionibacterium acnes* associated with inflammation in

- radical prostatectomy specimens: a possible link to cancer evolution? *J. Urol.* 173 (6), 1969–1974.
- Cronin, M., et al., 2010. Orally administered bifidobacteria as vehicles for delivery of agents to systemic tumors. *Mol. Ther.* 18 (7), 1397–1407.
- Dailhere, R., et al., 2016. *Enterococcus hirae* and *Barnesiella intestinihominis* facilitate cyclophosphamide-induced therapeutic immunomodulatory effects. *Immunity* 45 (4), 931–943.
- Daliri, E.B., et al., 2017. The human microbiome and metabolomics: current concepts and applications. *Crit. Rev. Food Sci. Nutr.* 57 (16), 3565–3576.
- Dang, D., et al., 2013. Meta-analysis of probiotics and/or prebiotics for the prevention of eczema. *J. Int. Med. Res.* 41 (5), 1426–1436.
- De Marco, C., et al., 2017. Specific gene expression signatures induced by the multiple oncogenic alterations that occur within the PTEN/PI3K/AKT pathway in lung cancer. *PLoS One* 12 (6), e0178865.
- de Martel, C., et al., 2009. *Helicobacter* species in cancers of the gallbladder and extrahepatic biliary tract. *Br. J. Cancer* 100 (1), 194–199.
- Derosa, L., et al., 2018. Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer. *Ann. Oncol.* 29 (6), 1437–1444.
- Di Domenico, E.G., et al., 2017. Biofilm producing *Salmonella typhi*: chronic colonization and development of gallbladder cancer. *Int. J. Mol. Sci.* 18 (9).
- Dinan, T.G., Cryan, J.F., 2017. The microbiome-gut-brain Axis in health and disease. *Gastroenterol. Clin. North Am.* 46 (1), 77–89.
- Ding, T., Schloss, P.D., 2014. Dynamics and associations of microbial community types across the human body. *Nature* 509 (7500), 357–360.
- Dominguez-Bello, M.G., et al., 2010. Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns. *Proc. Natl. Acad. Sci. U. S. A.* 107 (26), 11971–11975.
- Eslamiparast, T., et al., 2014. Synbiotic supplementation in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled pilot study. *Am. J. Clin. Nutr.* 99 (3), 535–542.
- Fan, X., et al., 2018a. Drinking alcohol is associated with variation in the human oral microbiome in a large study of American adults. *Microbiome* 6 (1), 59.
- Fan, X., et al., 2018b. Human oral microbiome and prospective risk for pancreatic cancer: a population-based nested case-control study. *Gut* 67 (1), 120–127.
- Ferreira, M.R., et al., 2014. Microbiota and radiation-induced bowel toxicity: lessons from inflammatory bowel disease for the radiation oncologist. *Lancet Oncol.* 15 (3), e139–47.
- Flanagan, L., et al., 2014. *Fusobacterium nucleatum* associates with stages of colorectal neoplasia development, colorectal cancer and disease outcome. *Eur. J. Clin. Microbiol. Infect. Dis.* 33 (8), 1381–1390.
- Flemer, B., et al., 2017. Tumour-associated and non-tumour-associated microbiota in colorectal cancer. *Gut* 66 (4), 633–643.
- Flemer, B., et al., 2018. The oral microbiota in colorectal cancer is distinctive and predictive. *Gut* 67 (8), 1454–1463.
- Floch, P., Megraud, F., Lehours, P., 2017. *Helicobacter pylori* strains and gastric MALT lymphoma. *Toxins (Basel)* 9 (4).
- Forbes, J.D., Van Domselaar, G., Bernstein, C.N., 2016. Microbiome survey of the inflamed and noninflamed gut at different compartments within the gastrointestinal tract of inflammatory bowel disease patients. *Inflamm. Bowel Dis.* 22 (4), 817–825.
- Franzosa, E.A., et al., 2014. Relating the metatranscriptome and metagenome of the human gut. *Proc. Natl. Acad. Sci. U. S. A.* 111 (22), E2329–38.
- Fujimura, K.E., et al., 2016. Neonatal gut microbiota associates with childhood multi-sensitized atopy and T cell differentiation. *Nat. Med.* 22 (10), 1187–1191.
- Fung, T.C., Olson, C.A., Hsiao, E.Y., 2017. Interactions between the microbiota, immune and nervous systems in health and disease. *Nat. Neurosci.* 20 (2), 145–155.
- Gao, Z., et al., 2015. Microbiota dysbiosis is associated with colorectal cancer. *Front. Microbiol.* 6, 20.
- Gao, R., et al., 2017a. Mucosa-associated microbiota signature in colorectal cancer. *Eur. J. Clin. Microbiol. Infect. Dis.* 36 (11), 2073–2083.
- Gao, J., et al., 2017b. Identification and functional analysis of risk-related microRNAs for the prognosis of patients with bladder urothelial carcinoma. *Oncol. Lett.* 14 (6), 7297–7303.
- Geller, L.T., et al., 2017. Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine. *Science* 357 (6356), 1156–1160.
- Goedert, J.J., et al., 2015. Investigation of the association between the fecal microbiota and breast cancer in postmenopausal women: a population-based case-control pilot study. *J. Natl. Cancer Inst.* 107 (8).
- Golombos, D.M., et al., 2018. The role of gut microbiome in the pathogenesis of prostate cancer: a prospective, pilot study. *Urology* 111, 122–128.
- Gong, H., et al., 2017. Alterations of microbiota structure in the larynx relevant to laryngeal carcinoma. *Sci. Rep.* 7 (1), 5507.
- Gopalakrishnan, V., et al., 2018. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. *Science* 359 (6371), 97–103.
- Gouveia, M.J., et al., 2015. Estrogen-like metabolites and DNA-adducts in urogenital schistosomiasis-associated bladder cancer. *Cancer Lett.* 359 (2), 226–232.
- Grat, M., et al., 2016. Profile of gut microbiota associated with the presence of hepatocellular cancer in patients with liver cirrhosis. *Transplant. Proc.* 48 (5), 1687–1691.
- Greathouse, K.L., et al., 2018. Interaction between the microbiome and TP53 in human lung cancer. *Genome Biol.* 19 (1), 123.
- Gui, Q.F., et al., 2015. Well-balanced commensal microbiota contributes to anti-cancer response in a lung cancer mouse model. *Genet. Mol. Res.* 14 (2), 5642–5651.
- Hale, V.L., et al., 2018. Distinct microbes, metabolites, and ecologies define the microbiome in deficient and proficient mismatch repair colorectal cancers. *Genome Med.* 10 (1), 78.
- Hamada, T., et al., 2018. *Fusobacterium nucleatum* in colorectal Cancer Relates to immune response differentially by tumor microsatellite instability status. *Cancer Immunol. Res.* 6 (11), 1327–1336.
- Hao, Q., et al., 2016. Systematic meta-analyses of gene-specific genetic association studies in prostate cancer. *Oncotarget* 7 (16), 22271–22284.
- Hasegawa, A., et al., 2014. Detection and identification of oral anaerobes in intraoperative bronchial fluids of patients with pulmonary carcinoma. *Microbiol. Immunol.* 58 (7), 375–381.
- He, Z., et al., 2018. *Campylobacter jejuni* promotes colorectal tumorigenesis through the action of cytolethal distending toxin. *Gut*.
- Hieken, T.J., et al., 2016. The microbiome of aseptically collected human breast tissue in benign and malignant disease. *Sci. Rep.* 6, 30751.
- Hill, C., et al., 2014. Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. *Nat. Rev. Gastroenterol. Hepatol.* 11 (8), 506–514.
- Hojo, M., et al., 2018. Gut microbiota composition before and after use of proton pump inhibitors. *Dig. Dis. Sci.* 63 (11), 2940–2949.
- Hosgood 3rd, H.D., et al., 2014. The potential role of lung microbiota in lung cancer attributed to household coal burning exposures. *Environ. Mol. Mutagen.* 55 (8), 643–651.
- Housseau, F., et al., 2016. Redundant innate and adaptive sources of IL17 production drive Colon tumorigenesis. *Cancer Res.* 76 (8), 2115–2124.
- Hsiao, J.R., et al., 2018. The interplay between oral microbiome, lifestyle factors and genetic polymorphisms in the risk of oral squamous cell carcinoma. *Carcinogenesis* 39 (6), 778–787.
- Human Microbiome Project, C, 2012a. A framework for human microbiome research. *Nature* 486 (7402), 215–221.
- Human Microbiome Project, C, 2012b. Structure, function and diversity of the healthy human microbiome. *Nature* 486 (7402), 207–214.
- Humans, I.W.G.o.t.E.o.C.R.t. and C, 2012. International Agency for Research on, a Review of Human Carcinogens. International Agency for Research on, a Review of Human Carcinogens.
- Iida, N., et al., 2013. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. *Science* 342 (6161), 967–970.
- Ito, M., et al., 2015. Association of *Fusobacterium nucleatum* with clinical and molecular features in colorectal serrated pathway. *Int. J. Cancer* 137 (6), 1258–1268.
- Jackson, L.A., et al., 2000. Association of *Chlamydia pneumoniae* immunoglobulin A seropositivity and risk of lung cancer. *Cancer Epidemiol. Biomarkers Prev.* 9 (11), 1263–1266.
- Jalanka, J., et al., 2015. Effects of bowel cleansing on the intestinal microbiota. *Gut* 64 (10), 1562–1568.
- Janda, J.M., Abbott, S.L., 2007. 16S rRNA gene sequencing for bacterial identification in the diagnostic laboratory: pluses, perils, and pitfalls. *J. Clin. Microbiol.* 45 (9), 2761–2764.
- Javurek, A.B., et al., 2016. Discovery of a novel seminal fluid microbiome and influence of estrogen receptor alpha genetic status. *Sci. Rep.* 6, 23027.
- Jin, P., et al., 2017. Mining the fecal proteome: from biomarkers to personalised medicine. *Expert Rev. Proteomics* 14 (5), 445–459.
- Jungnickel, C., et al., 2015. Cigarette smoke-induced disruption of pulmonary barrier and bacterial translocation drive tumor-associated inflammation and growth. *Am. J. Physiol. Lung Cell Mol. Physiol.* 309 (6), L605–13.
- Jungnickel, C., et al., 2017. IL-17C mediates the recruitment of tumor-associated neutrophils and lung tumor growth. *Oncogene* 36 (29), 4182–4190.
- Kau, A.L., et al., 2011. Human nutrition, the gut microbiome and the immune system. *Nature* 474 (7351), 327–336.
- Keay, S., et al., 1999. Polymerase chain reaction amplification of bacterial 16S rRNA genes in prostate biopsies from men without chronic prostatitis. *Urology* 53 (3), 487–491.
- Khazaie, K., et al., 2012. Abating colon cancer polyposis by *Lactobacillus acidophilus* deficient in lipoteichoic acid. *Proc. Natl. Acad. Sci. U. S. A.* 109 (26), 10462–10467.
- Klimesova, K., Jiraskova Zakostelska, Z., Tlaskalova-Hogenova, H., 2018. Oral bacterial and fungal microbiome impacts colorectal carcinogenesis. *Front. Microbiol.* 9, 774.
- Koi, M., Okita, Y., Carethers, J.M., 2018. *Fusobacterium nucleatum* infection in colorectal cancer: linking inflammation, DNA mismatch repair and genetic and epigenetic alterations. *J. Anus Rectum Colon* 2 (2), 37–46.
- Komiya, Y., et al., 2018. Patients with colorectal cancer have identical strains of *Fusobacterium nucleatum* in their colorectal cancer and oral cavity. *Gut*.
- Kostic, A.D., et al., 2012. Genomic analysis identifies association of *Fusobacterium* with colorectal carcinoma. *Genome Res.* 22 (2), 292–298.
- Kostic, A.D., et al., 2013. *Fusobacterium nucleatum* potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. *Cell Host Microbe* 14 (2), 207–215.
- Kosumi, K., et al., 2018. The amount of *Bifidobacterium* genus in colorectal carcinoma tissue in relation to tumor characteristics and clinical outcome. *Am. J. Pathol.* 188 (12), 2839–2852.
- Krieger, J.N., et al., 2000. Bacterial dna sequences in prostate tissue from patients with prostate cancer and chronic prostatitis. *J. Urol.* 164 (4), 1221–1228.
- Krishnan, S., Eslick, G.D., 2014. *Streptococcus bovis* infection and colorectal neoplasia: a meta-analysis. *Colorectal Dis.* 16 (9), 672–680.
- Lalla, R.V., et al., 2014. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. *Cancer* 120 (10), 1453–1461.
- Lam, K.C., et al., 2018. Transkingdom network reveals bacterial players associated with cervical cancer gene expression program. *PeerJ* 6, e5590.
- Le Noci, V., et al., 2018. Modulation of pulmonary microbiota by antibiotic or probiotic aerosol therapy: a strategy to promote immunosurveillance against lung metastases. *Cell Rep.* 24 (13), 3528–3538.
- Lee, S.H., et al., 2016a. Characterization of microbiome in bronchoalveolar lavage fluid of

- patients with lung cancer comparing with benign mass like lesions. *Lung Cancer* 102, 89–95.
- Lee, C.H., et al., 2016b. Frozen vs fresh fecal microbiota transplantation and clinical resolution of diarrhea in patients with recurrent *Clostridium difficile* infection: a randomized clinical trial. *JAMA* 315 (2), 142–149.
- Lee, D.W., et al., 2018. Association between *Fusobacterium nucleatum*, pathway mutation, and patient prognosis in colorectal cancer. *Ann. Surg. Oncol.* 25 (11), 3389–3395.
- Lim, Y., et al., 2018. The performance of an oral microbiome biomarker panel in predicting oral cavity and oropharyngeal cancers. *Front. Cell. Infect. Microbiol.* 8, 267.
- Liss, M.A., et al., 2018. Metabolic biosynthesis pathways identified from fecal microbiome associated with prostate cancer. *Eur. Urol.* 74 (5), 575–582.
- Liu, Y., et al., 2018a. *Streptococcus* and *Prevotella* are associated with the prognosis of oesophageal squamous cell carcinoma. *J. Med. Microbiol.* 67 (8), 1058–1068.
- Liu, Y., et al., 2018b. Lung tissue microbial profile in lung cancer is distinct from emphysema. *Am. J. Cancer Res.* 8 (9), 1775–1787.
- Liu, H.X., et al., 2018c. Difference of lower airway microbiome in bilateral protected specimen brush between lung cancer patients with unilateral lobar masses and control subjects. *Int. J. Cancer* 142 (4), 769–778.
- Liu, X., et al., 2018d. ESR1 PvuII (rs2234693 T > C) polymorphism and cancer susceptibility: evidence from 80 studies. *J. Cancer* 9 (16), 2963–2972.
- Lu, Y., et al., 2016. Mucosal adherent bacterial dysbiosis in patients with colorectal adenomas. *Sci. Rep.* 6, 26337.
- Luu, T.H., et al., 2017. Intestinal proportion of *Blautia* sp. is associated with clinical stage and histoprognostic grade in patients with early-stage breast cancer. *Nutr. Cancer* 69 (2), 267–275.
- Lynch, S.V., Pedersen, O., 2016. The human intestinal microbiome in health and disease. *N. Engl. J. Med.* 375 (24), 2369–2379.
- Ma, H., et al., 2018. Correlation between microbes and colorectal cancer: tumor apoptosis is induced by sitosterols through promoting gut microbiota to produce short-chain fatty acids. *Apoptosis*.
- Maisonneuve, P., Amar, S., Lowenfels, A.B., 2017. Periodontal disease, edentulism, and pancreatic cancer: a meta-analysis. *Ann. Oncol.* 28 (5), 985–995.
- Mao, Q., et al., 2018. Interplay between the lung microbiome and lung cancer. *Cancer Lett.* 415, 40–48.
- Markowiak, P., Slizewska, K., 2017. Effects of probiotics, prebiotics, and synbiotics on human health. *Nutrients* 9 (9).
- Maroof, H., et al., 2012. *Lactobacillus acidophilus* could modulate the immune response against breast cancer in murine model. *J. Clin. Immunol.* 32 (6), 1353–1359.
- Matson, V., et al., 2018. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. *Science* 359 (6371), 104–108.
- Maynard, C.L., et al., 2012. Reciprocal interactions of the intestinal microbiota and immune system. *Nature* 489 (7415), 231–241.
- McCarron, S.L., et al., 2002. Influence of cytokine gene polymorphisms on the development of prostate cancer. *Cancer Res.* 62 (12), 3369–3372.
- McDonald, D., et al., 2018. American gut: an open platform for citizen science microbiome research. *mSystems* 3 (3).
- Meng, S., et al., 2018. Study of Microbiomes in aseptically collected samples of human breast tissue using needle biopsy and the potential role of in situ tissue microbiomes for promoting malignancy. *Front. Oncol.* 8, 318.
- Mima, K., et al., 2015. *Fusobacterium nucleatum* and t cells in colorectal carcinoma. *JAMA Oncol.* 1 (5), 653–661.
- Mima, K., et al., 2016. *Fusobacterium nucleatum* in colorectal carcinoma tissue and patient prognosis. *Gut* 65 (12), 1973–1980.
- Mishiro, T., et al., 2018. Oral microbiome alterations of healthy volunteers with proton pump inhibitor. *J. Gastroenterol. Hepatol.* 33 (5), 1059–1066.
- Mitsuhashi, A., Okuma, Y., 2018. Perspective on immune oncology with liquid biopsy, peripheral blood mononuclear cells, and microbiome with non-invasive biomarkers in cancer patients. *Clin. Transl. Oncol.* 20 (8), 966–974.
- Mitsuhashi, K., et al., 2015. Association of *Fusobacterium* species in pancreatic cancer tissues with molecular features and prognosis. *Oncotarget* 6 (9), 7209–7220.
- Moayyedi, P., et al., 2015. Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. *Gastroenterology* 149 (1), 102–109 e6.
- Montassier, E., et al., 2015. Chemotherapy-driven dysbiosis in the intestinal microbiome. *Aliment. Pharmacol. Ther.* 42 (5), 515–528.
- Motoori, M., et al., 2017. Randomized study of the effect of synbiotics during neoadjuvant chemotherapy on adverse events in esophageal cancer patients. *Clin. Nutr.* 36 (1), 93–99.
- Mowry, E.M., Glenn, J.D., 2018. The dynamics of the gut microbiome in multiple sclerosis in relation to disease. *Neurol. Clin.* 36 (1), 185–196.
- Mukherjee, P.K., et al., 2017. Bacteriome and mycobiome associations in oral tongue cancer. *Oncotarget* 8 (57), 97273–97289.
- Murata, H., et al., 2004. *Helicobacter bilis* infection in biliary tract cancer. *Aliment. Pharmacol. Ther.* 20 (Suppl. 1), 90–94.
- Murphy, C., et al., 2017. Intratumoural production of TNF α by bacteria mediates cancer therapy. *PLoS One* 12 (6) p. e0180034.
- Murray-Stewart, T.R., Woster, P.M., Casero Jr., R.A., 2016. Targeting polyamine metabolism for cancer therapy and prevention. *Biochem. J.* 473 (19), 2937–2953.
- Naito, S., et al., 2008. Prevention of recurrence with epirubicin and *Lactobacillus casei* after transurethral resection of bladder cancer. *J. Urol.* 179 (2), 485–490.
- Nakatsu, G., et al., 2015. Gut mucosal microbiome across stages of colorectal carcinogenesis. *Nat. Commun.* 6, 8727.
- O'Keefe, S.J., 2016. Diet, microorganisms and their metabolites, and colon cancer. *Nat. Rev. Gastroenterol. Hepatol.* 13 (12), 691–706.
- O'Keefe, S.J., et al., 2015. Fat, fibre and cancer risk in African Americans and rural Africans. *Nat. Commun.* 6, 6342.
- Oh, H.Y., et al., 2015. The association of uterine cervical microbiota with an increased risk for cervical intraepithelial neoplasia in Korea. *Clin. Microbiol. Infect.* 21 (7), 674 e1–9.
- Olson, S.H., et al., 2017. The oral microbiota in patients with pancreatic cancer, patients with IPMNs, and controls: a pilot study. *Cancer Causes Control* 28 (9), 959–969.
- Osterlund, P., et al., 2007. *Lactobacillus* supplementation for diarrhoea related to chemotherapy of colorectal cancer: a randomised study. *Br. J. Cancer* 97 (8), 1028–1034.
- Ou, J., et al., 2013. Diet, microbiota, and microbial metabolites in colon cancer risk in rural Africans and African Americans. *Am. J. Clin. Nutr.* 98 (1), 111–120.
- Pala, L., et al., 2019. Sex differences in efficacy and toxicity of systemic Cancer treatments: role of the microbiome. *J. Clin. Oncol.* 37 (5), 439.
- Palmer, C., et al., 2007. Development of the human infant intestinal microbiota. *PLoS Biol.* 5 (7), e177.
- Pei, A.Y., et al., 2010. Diversity of 16S rRNA genes within individual prokaryotic genomes. *Appl. Environ. Microbiol.* 76 (12), 3886–3897.
- Perales-Puchalt, A., et al., 2018. Frontline science: microbiota reconstitution restores intestinal integrity after cisplatin therapy. *J. Leukoc. Biol.* 103 (5), 799–805.
- Pushalkar, S., et al., 2018. The pancreatic cancer microbiome promotes oncogenesis by induction of innate and adaptive immune suppression. *Cancer Discov.* 8 (4), 403–416.
- Putzi, M.J., De Marzo, A.M., 2000. Morphologic transitions between proliferative inflammatory atrophy and high-grade prostatic intraepithelial neoplasia. *Urology* 56 (5), 828–832.
- Quince, C., et al., 2017. Shotgun metagenomics, from sampling to analysis. *Nat. Biotechnol.* 35 (9), 833–844.
- Rafter, J., et al., 2007. Dietary synbiotics reduce cancer risk factors in polypectomized and colon cancer patients. *Am. J. Clin. Nutr.* 85 (2), 488–496.
- Raju, S.C., et al., 2019. Gender-specific associations between saliva microbiota and body size. *Front. Microbiol.* 10, 767.
- Rao, V.P., et al., 2006. Proinflammatory CD4+ CD45RB(hi) lymphocytes promote mammary and intestinal carcinogenesis in Apc(Min/+) mice. *Cancer Res.* 66 (1), 57–61.
- Ren, R., et al., 2018. The gastric mucosal-associated microbiome in patients with gastric polyposis. *Sci. Rep.* 8 (1), 13817.
- Repass, J., et al., 2016. Registered report: *Fusobacterium nucleatum* infection is prevalent in human colorectal carcinoma. *Elife* 5.
- Rioux-Leclercq, N., et al., 2004. Immunohistochemical analysis of tumor polyamines discriminates high-risk patients undergoing nephrectomy for renal cell carcinoma. *Hum. Pathol.* 35 (10), 1279–1284.
- Ritchie, M.L., Romanuk, T.N., 2012. A meta-analysis of probiotic efficacy for gastrointestinal diseases. *PLoS One* 7 (4), e34938.
- Roberfroid, M., et al., 2010. Prebiotic effects: metabolic and health benefits. *Br. J. Nutr.* 104 (Suppl. 2), S1–63.
- Rodriguez, M., Wootla, B., Anderson, G., 2016. Multiple sclerosis, gut microbiota and permeability: role of tryptophan catabolites, depression and the driving down of local melatonin. *Curr. Pharm. Des.* 22 (40), 6134–6141.
- Roediger, W.E., 1982. Utilization of nutrients by isolated epithelial cells of the rat colon. *Gastroenterology* 83 (2), 424–429.
- Rogers, A.B., 2011. Distance burning: how gut microbes promote extraintestinal cancers. *Gut Microbes* 2 (1), 52–57.
- Rong, J., et al., 2018. Single probiotic supplement suppresses colitis-associated colorectal tumorigenesis by modulating inflammatory development and microbial homeostasis. *J. Gastroenterol. Hepatol.*
- Rosshart, S.P., et al., 2017. Wild mouse gut microbiota promotes host fitness and improves disease resistance. *Cell* 171 (5), 1015–1028 e13.
- Routy, B., et al., 2018. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. *Science* 359 (6371), 91–97.
- Rubinstein, M.R., et al., 2013. *Fusobacterium nucleatum* promotes colorectal carcinogenesis by modulating E-cadherin/ β -catenin signaling via its FadA adhesin. *Cell Host Microbe* 14 (2), 195–206.
- Sandsmark, E., et al., 2017. A novel non-canonical Wnt signature for prostate cancer aggressiveness. *Oncotarget* 8 (6), 9572–9586.
- Sanz-Pamplona, R., et al., 2014. Aberrant gene expression in mucosa adjacent to tumor reveals a molecular crosstalk in colon cancer. *Mol. Cancer* 13, 46.
- Scheufele, F., et al., 2017. Effect of preoperative biliary drainage on bacterial flora in bile of patients with perianipillary cancer. *Br. J. Surg.* 104 (2), e182–e188.
- Schwabe, R.F., Jobin, C., 2013. The microbiome and cancer. *Nat. Rev. Cancer* 13 (11), 800–812.
- Seo, S.S., et al., 2016. Combined effect of diet and cervical microbiome on the risk of cervical intraepithelial neoplasia. *Clin. Nutr.* 35 (6), 1434–1441.
- Sethi, V., et al., 2018. Gut microbiota promotes tumor growth in mice by modulating immune response. *Gastroenterology* 155 (1), 33–37 e6.
- Sfanos, K.S., et al., 2008. A molecular analysis of prokaryotic and viral DNA sequences in prostate tissue from patients with prostate cancer indicates the presence of multiple and diverse microorganisms. *Prostate* 68 (3), 306–320.
- Sfanos, K.S., et al., 2018. Compositional differences in gastrointestinal microbiota in prostate cancer patients treated with androgen axis-targeted therapies. *Prostate Cancer Prostatic Dis.* 21 (4), 539–548.
- Shinohara, D.B., et al., 2013. A mouse model of chronic prostatic inflammation using a human prostate cancer-derived isolate of *Propionibacterium acnes*. *Prostate* 73 (9), 1007–1015.
- Shrestha, E., et al., 2018. Profiling the urinary microbiome in men with positive versus negative biopsies for prostate Cancer. *J. Urol.* 199 (1), 161–171.
- Simons, B.W., et al., 2015. A human prostatic bacterial isolate alters the prostatic microenvironment and accelerates prostate cancer progression. *J. Pathol.* 235 (3), 478–489.

- Singhal, N., et al., 2015. MALDI-TOF mass spectrometry: an emerging technology for microbial identification and diagnosis. *Front. Microbiol.* 6, 791.
- Sivan, A., et al., 2015. Commensal *Bifidobacterium* promotes antitumor immunity and facilitates anti-PD-L1 efficacy. *Science* 350 (6264), 1084–1089.
- Sonnenburg, J.L., Backhed, F., 2016. Diet-microbiota interactions as moderators of human metabolism. *Nature* 535 (7610), 56–64.
- Syed Khaja, A.S., et al., 2017. Preferential accumulation of regulatory T cells with highly immunosuppressive characteristics in breast tumor microenvironment. *Oncotarget* 8 (20), 33159–33171.
- Tahara, T., et al., 2014. *Fusobacterium* in colonic flora and molecular features of colorectal carcinoma. *Cancer Res.* 74 (5), 1311–1318.
- Tang, W.H., et al., 2013. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. *N. Engl. J. Med.* 368 (17), 1575–1584.
- Taylor, A.M., et al., 2019. Associations among diet, the gastrointestinal microbiota, and negative emotional states in adults. *Nutr. Neurosci.* 1–10.
- Thompson, K.J., et al., 2017. A comprehensive analysis of breast cancer microbiota and host gene expression. *PLoS One* 12 (11), e0188873.
- Tomkovich, S., et al., 2017. Locoregional effects of microbiota in a preclinical model of Colon carcinogenesis. *Cancer Res.* 77 (10), 2620–2632.
- Tsay, J.J., et al., 2018. Airway microbiota is associated with upregulation of the PI3K pathway in lung Cancer. *Am. J. Respir. Crit. Care Med.* 198 (9), 1188–1198.
- Uemura, N., et al., 2001. *Helicobacter pylori* infection and the development of gastric cancer. *N. Engl. J. Med.* 345 (11), 784–789.
- Urbaniak, C., et al., 2016. The microbiota of breast tissue and its association with breast Cancer. *Appl. Environ. Microbiol.* 82 (16), 5039–5048.
- Uribe-Herranz, M., et al., 2018. Gut microbiota modulates adoptive cell therapy via CD8alpha dendritic cells and IL-12. *JCI Insight* 3 (4).
- Vaishnavi, C., Samanta, J., Kochhar, R., 2018. Characterization of biofilms in biliary stents and potential factors involved in occlusion. *World J. Gastroenterol.* 24 (1), 112–123.
- van Nood, E., et al., 2013. Duodenal infusion of donor feces for recurrent *Clostridium difficile*. *N. Engl. J. Med.* 368 (5), 407–415.
- Viaud, S., et al., 2013. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. *Science* 342 (6161), 971–976.
- Vipperla, K., O'Keefe, S.J., 2012. The microbiota and its metabolites in colonic mucosal health and cancer risk. *Nutr. Clin. Pract.* 27 (5), 624–635.
- Vogtmann, E., et al., 2015. Association between tobacco use and the upper gastrointestinal microbiome among Chinese men. *Cancer Causes Control* 26 (4), 581–588.
- Vrieze, A., et al., 2012. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. *Gastroenterology* 143 (4), 913–916 e7.
- Walther-Antonio, M.R., et al., 2016. Potential contribution of the uterine microbiome in the development of endometrial cancer. *Genome Med.* 8 (1), 122.
- Wang, Y., Qian, P.Y., 2009. Conservative fragments in bacterial 16S rRNA genes and primer design for 16S ribosomal DNA amplicons in metagenomic studies. *PLoS One* 4 (10), e7401.
- Wang, T., et al., 2012a. Structural segregation of gut microbiota between colorectal cancer patients and healthy volunteers. *ISME J.* 6 (2), 320–329.
- Wang, H.B., et al., 2012b. Butyrate enhances intestinal epithelial barrier function via up-regulation of tight junction protein Claudin-1 transcription. *Dig. Dis. Sci.* 57 (12), 3126–3135.
- Wang, Y., et al., 2018. Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. *Nat. Med.* 24 (12), 1804–1808.
- Wei, M.Q., et al., 2007. Facultative or obligate anaerobic bacteria have the potential for multimodality therapy of solid tumours. *Eur. J. Cancer* 43 (3), 490–496.
- Whiteside, S.A., et al., 2015. The microbiome of the urinary tract—a role beyond infection. *Nat. Rev. Urol.* 12 (2), 81–90.
- Willemsen, L.E., et al., 2003. Short chain fatty acids stimulate epithelial mucin 2 expression through differential effects on prostaglandin E(1) and E(2) production by intestinal myofibroblasts. *Gut* 52 (10), 1442–1447.
- Wolfe, A.J., et al., 2012. Evidence of uncultivated bacteria in the adult female bladder. *J. Clin. Microbiol.* 50 (4), 1376–1383.
- Wu, S., et al., 2009. A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. *Nat. Med.* 15 (9), 1016–1022.
- Wu, H., et al., 2017. Metformin alters the gut microbiome of individuals with treatment-naïve type 2 diabetes, contributing to the therapeutic effects of the drug. *Nat. Med.* 23 (7), 850–858.
- Wu, J., et al., 2018a. Tongue coating microbiota community and risk effect on gastric Cancer. *J. Cancer* 9 (21), 4039–4048.
- Wu, P., et al., 2018b. Profiling the urinary microbiota in male patients with bladder Cancer in China. *Front. Cell. Infect. Microbiol.* 8, 167.
- Xie, G., et al., 2016. Distinctly altered gut microbiota in the progression of liver disease. *Oncotarget* 7 (15), 19355–19366.
- Xuan, C., et al., 2014. Microbial dysbiosis is associated with human breast cancer. *PLoS One* 9 (1), e83744.
- Yang, Y., et al., 2017. *Fusobacterium nucleatum* increases proliferation of colorectal cancer cells and tumor development in mice by activating toll-like receptor 4 signaling to nuclear Factor-kappaB, and up-regulating expression of MicroRNA-21. *Gastroenterology* 152 (4), 851–866 e24.
- Yang, C.Y., et al., 2018a. Oral microbiota community dynamics associated with oral squamous cell carcinoma staging. *Front. Microbiol.* 9, 862.
- Yang, Y., et al., 2018b. Prospective study of oral microbiome and colorectal cancer risk in low-income and African American populations. *Int. J. Cancer.*
- Yongvanit, P., Pinlaor, S., Bartsch, H., 2012. Oxidative and nitrate DNA damage: key events in opisthorchiasis-induced carcinogenesis. *Parasitol. Int.* 61 (1), 130–135.
- Yoshimoto, S., et al., 2013. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. *Nature* 499 (7456), 97–101.
- Yost, S., et al., 2018. Increased virulence of the oral microbiome in oral squamous cell carcinoma revealed by metatranscriptome analyses. *Int. J. Oral Sci.* 10 (4), 32.
- Yow, M.A., et al., 2017. Characterisation of microbial communities within aggressive prostate cancer tissues. *Infect Agent Cancer* 12, 4.
- Yu, Y.N., et al., 2015a. Berberine may rescue *Fusobacterium nucleatum*-induced colorectal tumorigenesis by modulating the tumor microenvironment. *Oncotarget* 6 (31), 32013–32026.
- Yu, H., et al., 2015b. Urinary microbiota in patients with prostate cancer and benign prostatic hyperplasia. *Arch. Med. Sci.* 11 (2), 385–394.
- Yu, G., et al., 2016. Characterizing human lung tissue microbiota and its relationship to epidemiological and clinical features. *Genome Biol.* 17 (1), 163.
- Yu, T., et al., 2017. *Fusobacterium nucleatum* promotes chemoresistance to colorectal Cancer by modulating autophagy. *Cell* 170 (3), 548–563 e16.
- Yuan, C., et al., 2018. Interaction between host MicroRNAs and the gut microbiota in colorectal Cancer. *mSystems* 3 (3).
- Zhan, P., et al., 2011. *Chlamydia pneumoniae* infection and lung cancer risk: a meta-analysis. *Eur. J. Cancer* 47 (5), 742–747.
- Zhang, M.M., et al., 2010. Use of pre-, pro- and synbiotics in patients with acute pancreatitis: a meta-analysis. *World J. Gastroenterol.* 16 (31), 3970–3978.
- Zhang, W.Q., et al., 2018. Alterations of fecal bacterial communities in patients with lung cancer. *Am. J. Transl. Res.* 10 (10), 3171–3185.
- Zhou, Z., et al., 2018. *Fusobacterium* and colorectal cancer. *Front. Oncol.* 8, 371.
- Zhu, H., et al., 2016. *Chlamydia trachomatis* infection-associated risk of cervical cancer: a meta-analysis. *Medicine (Baltimore)* 95 (13), e3077.
- Zhu, J., et al., 2018. Breast cancer in postmenopausal women is associated with an altered gut metagenome. *Microbiome* 6 (1), 136.

Sarah L. Picardo, MB BCh BAO, PhD, is a Clinical Research Fellow at Princess Margaret Cancer Centre, Toronto, Canada.

Bryan Coburn, MD, PhD, FRCPC, is Assistant Professor in Infectious Diseases and Immunopathology at University Health Network, Toronto, Canada.

Aaron Hansen, BSc, MBBS, FRACP, is Assistant Professor and Genitourinary Site Lead in Medical Oncology at Princess Margaret Cancer Centre, Toronto, Canada.